ATE326239T1 - Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren - Google Patents
Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahrenInfo
- Publication number
- ATE326239T1 ATE326239T1 AT99948333T AT99948333T ATE326239T1 AT E326239 T1 ATE326239 T1 AT E326239T1 AT 99948333 T AT99948333 T AT 99948333T AT 99948333 T AT99948333 T AT 99948333T AT E326239 T1 ATE326239 T1 AT E326239T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- compositions
- treating
- ige
- associated diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10083898P | 1998-09-18 | 1998-09-18 | |
US13660099P | 1999-05-28 | 1999-05-28 | |
US39719899A | 1999-09-16 | 1999-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE326239T1 true ATE326239T1 (de) | 2006-06-15 |
Family
ID=27379083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99948333T ATE326239T1 (de) | 1998-09-18 | 1999-09-17 | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren |
Country Status (9)
Country | Link |
---|---|
US (2) | US20030064064A1 (de) |
EP (1) | EP1113818B1 (de) |
JP (1) | JP2003524602A (de) |
AT (1) | ATE326239T1 (de) |
AU (1) | AU766492B2 (de) |
CA (1) | CA2343052A1 (de) |
DE (1) | DE69931377T2 (de) |
ES (1) | ES2259478T3 (de) |
WO (1) | WO2000016804A1 (de) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
IL139646A0 (en) * | 1998-05-14 | 2002-02-10 | Coley Pharm Group Inc | Methods for regulating hematopoiesis using cpg-oligonucleotides |
FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US20010046967A1 (en) | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
US7157437B2 (en) | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
EP1278550A4 (de) * | 2000-04-07 | 2004-05-12 | Univ California | Synergistische verbesserungen von polynucleotid impfstoffen |
US6787524B2 (en) | 2000-09-22 | 2004-09-07 | Tanox, Inc. | CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies |
EP1364010B1 (de) | 2000-12-27 | 2010-06-16 | Dynavax Technologies Corporation | Immunomodulatorische polynukleotide und verfahren zur deren verwendung |
WO2002092125A1 (en) * | 2001-05-11 | 2002-11-21 | Novartis Ag | Compositions for use in treating ige-associated disorders |
MXPA03010507A (es) * | 2001-05-15 | 2005-07-25 | Johnson & Johnson | Activacion ex vivo para generar linfocitos c citotoxicos espedificos para antigenos no tumorales para tratar enfermedades autoinmunes y alergicas. |
EP2423335B1 (de) | 2001-06-21 | 2014-05-14 | Dynavax Technologies Corporation | Chimäre immunmodulierende Verbindungen und Verwendungsverfahren dafür |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
US20030133988A1 (en) | 2001-08-07 | 2003-07-17 | Fearon Karen L. | Immunomodulatory compositions, formulations, and methods for use thereof |
AU2002361468A1 (en) * | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
WO2003015744A1 (en) * | 2001-08-16 | 2003-02-27 | Medical Research Council | Chitin microparticles and their medical uses |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
GB0200429D0 (en) * | 2002-01-09 | 2002-02-27 | Novartis Ag | Organic compounds |
US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
EP1575977B1 (de) | 2002-12-23 | 2009-09-09 | Dynavax Technologies Corporation | Oligonukleotide mit einer immunsystemstimulierenden sequenz und verfahren zu deren anwendung |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
TWI235440B (en) * | 2004-03-31 | 2005-07-01 | Advanced Semiconductor Eng | Method for making leadless semiconductor package |
CA2567789A1 (en) * | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
CA2600036A1 (en) | 2005-03-04 | 2006-09-14 | Dynavax Technologies Corporation | Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients |
JP2008535859A (ja) * | 2005-04-08 | 2008-09-04 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 感染症によって悪化した喘息を治療するための方法 |
EP1991678B2 (de) * | 2006-02-15 | 2020-07-15 | Rechtsanwalt Thomas Beck | Zusammensetzungen und verfahren für oligonukleotidformulierungen |
ES2900342T3 (es) | 2012-08-21 | 2022-03-16 | Sanofi Biotechnology | Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R |
TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
CN106062000B (zh) | 2014-02-28 | 2021-05-28 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗皮肤感染的方法 |
CN107206073A (zh) | 2014-11-14 | 2017-09-26 | 赛诺菲生物技术公司 | 通过施用il‑4r拮抗剂用于治疗伴随鼻息肉的慢性鼻窦炎的方法 |
US10384291B2 (en) * | 2015-01-30 | 2019-08-20 | Lincoln Global, Inc. | Weld ending process and system |
MA46098A (fr) | 2016-09-01 | 2019-07-10 | Regeneron Pharma | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
US10485844B2 (en) | 2016-09-22 | 2019-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
CA3079946A1 (en) | 2017-10-30 | 2019-05-09 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
EP3793597A1 (de) | 2018-05-13 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Verfahren zur behandlung atopischer dermatitis durch verabreichung eines il-4r-inhibitors |
AU2020240132A1 (en) | 2019-03-21 | 2021-09-16 | Regeneron Pharmaceuticals, Inc. | Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy |
CA3147068A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US280005A (en) * | 1883-06-26 | baldwin | ||
US2676325A (en) * | 1952-08-02 | 1954-04-27 | Carlson Julius | Cap construction |
US4491632A (en) * | 1979-10-22 | 1985-01-01 | The Massachusetts General Hospital | Process for producing antibodies to hepatitis virus and cell lines therefor |
US4444887A (en) * | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
EP0043718B1 (de) * | 1980-07-07 | 1984-11-28 | National Research Development Corporation | Zellinien |
US4849513A (en) * | 1983-12-20 | 1989-07-18 | California Institute Of Technology | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups |
US5118800A (en) * | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
US5015733A (en) * | 1983-12-20 | 1991-05-14 | California Institute Of Technology | Nucleosides possessing blocked aliphatic amino groups |
US5118802A (en) * | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
US5026545A (en) * | 1984-09-17 | 1991-06-25 | Baxter International, Inc. | Treatment of allergy and composition therefor |
US4633530A (en) * | 1985-09-04 | 1987-01-06 | Satterfield Roy E | Protective device |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5449760A (en) * | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
US5614611A (en) * | 1987-12-31 | 1997-03-25 | Tanox Biosystems, Inc. | Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils |
US5422258A (en) * | 1987-12-31 | 1995-06-06 | Tanox Biosystems, Inc. | Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5391723A (en) * | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US5121507A (en) * | 1990-10-10 | 1992-06-16 | Brown Ronald R | Headwear accessory attachment |
US5125113A (en) * | 1991-04-30 | 1992-06-30 | Yun In Seo | Visored cap with front, side and rear shades |
CA2086605A1 (en) * | 1991-05-10 | 1992-11-11 | Alain De Weck | Procedure for detecting and preparing anti-ige autoantibodies and use of these antibodies as active agents in diagnostic and therapeutic compositions |
US5153943A (en) * | 1991-09-04 | 1992-10-13 | Clement Keith H | Weather-shield hat accessory |
US5849719A (en) * | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
DK0739214T3 (da) * | 1994-01-18 | 1998-10-07 | Genentech Inc | Fremgangsmåde til behandling af parasitinfektionerunder anvendelse af IgE antagonister |
US5426790A (en) * | 1994-02-25 | 1995-06-27 | Robertson; Stanley | Sun shield for head wear |
WO1995026204A1 (en) * | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
CA2194761C (en) * | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5493733A (en) * | 1994-09-09 | 1996-02-27 | Pospisil; Robert L. | Cap providing sun protection for ears |
US5762943A (en) * | 1996-05-14 | 1998-06-09 | Ribi Immunochem Research, Inc. | Methods of treating type I hypersensitivity using monophosphoryl lipid A |
WO1998037919A1 (en) * | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
ES2284247T3 (es) * | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos. |
US6079052A (en) * | 1999-07-19 | 2000-06-27 | Veridiano; Carlos H. | Headgear with removable forwardly extending side flaps |
US6550064B2 (en) * | 2001-01-17 | 2003-04-22 | Robert Schmitt | Ear shield apparatus |
-
1999
- 1999-09-17 DE DE69931377T patent/DE69931377T2/de not_active Expired - Lifetime
- 1999-09-17 EP EP99948333A patent/EP1113818B1/de not_active Expired - Lifetime
- 1999-09-17 WO PCT/US1999/021686 patent/WO2000016804A1/en active IP Right Grant
- 1999-09-17 JP JP2000573765A patent/JP2003524602A/ja active Pending
- 1999-09-17 AT AT99948333T patent/ATE326239T1/de active
- 1999-09-17 AU AU61537/99A patent/AU766492B2/en not_active Ceased
- 1999-09-17 CA CA002343052A patent/CA2343052A1/en not_active Abandoned
- 1999-09-17 ES ES99948333T patent/ES2259478T3/es not_active Expired - Lifetime
-
2002
- 2002-08-06 US US10/214,288 patent/US20030064064A1/en not_active Abandoned
-
2005
- 2005-05-17 US US11/132,163 patent/US20060013811A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2259478T3 (es) | 2006-10-01 |
CA2343052A1 (en) | 2000-03-30 |
EP1113818B1 (de) | 2006-05-17 |
AU6153799A (en) | 2000-04-10 |
EP1113818A1 (de) | 2001-07-11 |
US20030064064A1 (en) | 2003-04-03 |
DE69931377D1 (de) | 2006-06-22 |
WO2000016804A1 (en) | 2000-03-30 |
JP2003524602A (ja) | 2003-08-19 |
US20060013811A1 (en) | 2006-01-19 |
DE69931377T2 (de) | 2007-05-10 |
AU766492B2 (en) | 2003-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE326239T1 (de) | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren | |
BRPI0211200B8 (pt) | peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células | |
DE69703689D1 (de) | Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia | |
DE69826695D1 (de) | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen | |
BRPI0213786B8 (pt) | peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células | |
DE69833779D1 (de) | Verfahren und zusammensetzungen zur immunomodulation | |
DE60139689D1 (de) | Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs. | |
MY155218A (en) | Small molecules useful in the treatment of inflammatory disease | |
WO2003089457A3 (en) | Peptide inhibitors of protein kinase c ϝ for pain management | |
MY136095A (en) | Use of human anti-ctla-4 antibodies for treatment of cancer | |
ATE230417T1 (de) | Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien | |
ATE304350T1 (de) | Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen | |
ATE411016T1 (de) | Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten | |
ATE527022T1 (de) | Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie | |
ATE448775T1 (de) | Rifalazil zur behandlung von infektionen mit clostridium difficile | |
IL187254A (en) | ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB | |
DE60034871D1 (de) | Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust | |
DE60313434D1 (de) | Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen | |
ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
DE69839943D1 (de) | Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen | |
ATE419851T1 (de) | Verwendung von riluzol zur behandlung multipler sklerose | |
DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
ID23184A (id) | Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi | |
EP1671646A3 (de) | Verfahren zur Behandlung von IgE- assoziierten Krankheiten und Zusammensetzungen zur Verwendung in diesen Verfahren | |
ATE360425T1 (de) | Verwendung von quetiapin für die behandlung von kokain-abhängigkeit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1113818 Country of ref document: EP |